NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387
–News Direct– NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share exciting updates on their antiviral drug candidate, NV 387. The drug, developed in response to the …
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387 Read More